Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Genfit S.A. GNFT NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • FR • USD

SharesGrow Score
53/100
1/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$13.00
+45.3%

Genfit S.A. (GNFT) is a Biotechnology company in the Healthcare sector, currently trading at $8.95. It has a SharesGrow Score of 53/100, indicating a mixed investment profile with 1 out of 7 criteria passed.

Analyst consensus target is GNFT = $13 (+45.3% upside).

Financials: revenue is $67M, +33.7%/yr average growth. Net income is $2M, growing at -17.3%/yr. Net profit margin is 2.2% (thin). Gross margin is 99.6% (-0.2 pp trend).

Balance sheet: total debt is $62M against $69M equity (Debt-to-Equity (D/E) ratio 0.9, moderate). Current ratio is 1.23 (adequate). Debt-to-assets is 41%. Total assets: $151M.

Analyst outlook: 6 / 7 analysts rate GNFT as buy (86%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 57/100 (Partial), Growth 58/100 (Partial), Past 50/100 (Partial), Health 33/100 (Fail), Moat 46/100 (Partial), Future 94/100 (Pass), Income 30/100 (Fail).

$13.00
▲ 45.25% Upside
Average Price Target
The 12-month price target for Genfit S.A. is $13.00.

GNFT SharesGrow Score Overview

53/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 57/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 50/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 46/100
Gross margin is + market cap
FUTURE 94/100
Analyst outlook — as buy
INCOME 30/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — GNFT

~
VALUE Partial
57/100
GNFT trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $13, implying +45.3% from the current price $9. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
GNFT: +33.7%/yr revenue is, -17.3%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
~
PAST Partial
50/100
GNFT: 2 / 4 years profitable. weak. Score = 2 / 4 × 100. ≥ 80 = Pass.
View details →
✗
HEALTH Fail
33/100
Balance sheet GNFT: Debt-to-Equity (D/E) ratio 0.9 (moderate), Current ratio is 1.23 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
46/100
GNFT: Gross margin is 99.6% (-0.2 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 46/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
94/100
Analyst outlook: 6 / 7 analysts rate GNFT as buy (86%). Analyst consensus target is $13 (+45.3% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
30/100
GNFT: Net profit margin is 2.2%. thin (0-5%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range2.55-10
Volume4.21K
Avg Volume (30D)10.37K
Market Cap$445.68M
Beta (1Y)0.87
Share Statistics
EPS (TTM)0.03
Shares Outstanding$50.16M
IPO Date2019-03-27
Employees180
CEOM. Pascal Prigent
Financial Highlights & Ratios
Revenue (TTM)$67M
Gross Profit$66.7M
EBITDA$8.32M
Net Income$1.51M
Operating Income$3.28M
Total Cash$81.79M
Total Debt$62.13M
Net Debt$-19.66M
Total Assets$151.42M
Price / Earnings (P/E)275.4
Price / Sales (P/S)6.65
Analyst Forecast
1Y Price Target$13.00
Target High$13.00
Target Low$13.00
Upside+45.3%
Rating ConsensusBuy
Analysts Covering7
Buy 86% Hold 0% Sell 14%
Price Target Summary
Company Info
CountryFR
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS3722791098

Price Chart

Track all markets on TradingView
GNFT
Genfit S.A. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
2.55 52WK RANGE 10.00

People Also View

EWTX
EWTX
Edgewise Therapeutics, Inc.
$33.16
-2.01%
 HRMY
HRMY
Harmony Biosciences Holdings, Inc.
$29.29
+0.83%
 JANX
JANX
Janux Therapeutics, Inc.
$15.24
+2.28%
 KROS
KROS
Keros Therapeutics, Inc.
$11.55
+3.59%
 ELYM
ELYM
Eliem Therapeutics, Inc.
$5.11
-0.97%
 RZLT
RZLT
Rezolute, Inc.
$3.56
-1.36%
 FENC
FENC
Fennec Pharmaceuticals Inc.
$6.25
+5.40%
 MOLN
MOLN
Molecular Partners AG
$4.14
-1.66%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message